NCT Number: NCT00161863
Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
The purpose of this study is to investigate the safety of five consecutive lots of FSME-IMMUN NEW in healthy volunteers. The main criterion for investigation is the fever rate after the first vaccination in three different age classes. The immunogenicity of 0.25 ml FSME-IMMUN NEW has been demonstrated in previous clinical studies in children; therefore, in the present study, immunogenicity was investigated in a subgroup only.
Looking for future studies?
Notify MeKey information
Conditions
Age range
1 year–15 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Grieskirchner Strasse 17, Wels, Austria
Who can participate
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Male and female children and adolescents will be eligible for participation in this study if:
- they are aged 1 year (from the 1st birthday) to < 16 years (to the last day before the 16th birthday);
- they are clinically healthy, (i. e. the physician would have no reservations vaccinating with FSME-IMMUN NEW outside the scope of a clinical trial);
- their parents/legal guardians understand the nature of the study and agree to its provisions;
- written informed consent is available from both parents/legal guardians,
- for Germany/Austria: additional written informed consent is available for children older than 8 years
- they or their parents/legal guardians agree to keep a volunteer diary.
For safety reasons, female volunteers who have reached sexual maturity at study start have to meet the following additional inclusion criteria:
- negative pregnancy test at study entry;
Exclusion criteria
Children and adolescents will be excluded from participation in this study if they:
- have a history of any TBE vaccination;
- have a history of TBE infection;
- have a history of allergic reactions to one of the components of the vaccine;
- suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids, chemotherapeutics) that can be expected to influence immunological functions;
- are known to be HIV positive (a special HIV test is not required for the purpose of the study);
- have received banked blood or immunoglobulins within one month of study entry;
- have a history of vaccination against yellow fever and/or Japanese B-encephalitis;
- suffer from hemorrhagic diathesis;
- are participating simultaneously in another clinical trial;
- if female: are pregnant or breastfeeding.
Volunteers who meet the inclusion/exclusion criteria, but have a febrile illness (body temperature > 38°C) at the scheduled time of vaccination, will not be vaccinated before their body temperature returns to normal.
Volunteers who have received any other vaccination within 4 weeks prior to visit 1 will not be vaccinated until an interval of 4 weeks has passed. In this case visit 1 will take place separately.
If volunteers have received antipyretics within 4 hours prior to the intended TBE vaccination, the vaccination should be performed at a later time.
Volunteers who have a positive TBE antibody value prior to the first vaccination will be excluded from the statistical analysis of the primary endpoint.
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Pfizer
Industry
Registry information
Official study title
Open-label Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years
Important dates
- Study start
- 2002
- Study completion
- 2003
- First posted
- Sep 13, 2005
- Registry last updated
- May 21, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Tick-borne Encephalitis Virus Research in Limousin
NCT05941546
Arbovirus Infections, Brain Diseases
Limoges, France
View Trial DetailsStudy to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
NCT04648241
Arbovirus Infections, Brain Diseases
Fukuoka, Japan
View Trial DetailsNew Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly
NCT02318069
Arbovirus Infections, Brain Diseases
Helsinki, Finland
View Trial DetailsCervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac
NCT01710189
Arbovirus Infections, Brain Diseases
Guildford, Surrey, United Kingdom
View Trial Details